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The role of the cancer stem cell marker CD271 in DNA
damage response and drug resistance of melanoma cells
T Redmer1,2, I Walz2, B Klinger2,3, S Khouja2, Y Welte2, R Schäfer1,2 and C Regenbrecht2,4
Several lines of evidence have suggested that stemness and acquired resistance to targeted inhibitors or chemotherapeutics are
mechanistically linked. Here we observed high cell surface and total levels of nerve growth factor receptor/CD271, a marker of
melanoma-initiating cells, in sub-populations of chemoresistant cell lines. CD271 expression was increased in drug-sensitive cells
but not resistant cells in response to DNA-damaging chemotherapeutics etoposide, fotemustine and cisplatin. Comparative analysis
of melanoma cells engineered to stably express CD271 or a targeting short hairpin RNA by expression proﬁling provided numerous
genes regulated in a CD271-dependent manner. In-depth analysis of CD271-responsive genes uncovered the association of CD271
with regulation of DNA repair components. In addition, gene set enrichment analysis revealed enrichment of CD271-responsive
genes in drug-resistant cells, among them DNA repair components. Moreover, our comparative screen identiﬁed the ﬁbroblast
growth factor 13 (FGF13) as a target of CD271, highly expressed in chemoresistant cells. Further we show that levels of CD271
determine drug response. Knock-down of CD271 in fotemustine-resistant cells decreased expression of FGF13 and at least partly
restored sensitivity to fotemustine. Together, we demonstrate that expression of CD271 is responsible for genes associated with
DNA repair and drug response. Further, we identiﬁed 110 CD271-responsive genes predominantly expressed in melanoma
metastases, among them were NEK2, TOP2A and RAD51AP1 as potential drivers of melanoma metastasis. In addition, we provide
mechanistic insight in the regulation of CD271 in response to drugs. We found that CD271 is potentially regulated by p53 and in
turn is needed for a proper p53-dependent response to DNA-damaging drugs. In summary, we provide for the ﬁrst time insight in a
CD271-associated signaling network connecting CD271 with DNA repair, drug response and metastasis.
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INTRODUCTION
Despite recent progress in treatment options, malignant
melanoma metastasized to liver, lung or brain remains to be a
non-curable disease. Overall, the therapy of stage IV melanoma by
chemotherapeutics and targeted therapies results in median
progression-free survival of approximately 1.5–7 months and a
5-year survival period is observed for 10% of patients only. The
major obstacle to long-term patient survival is resistance acquired
under therapy. Although BRAFV600E mutated melanomas, which
represent 40–60% of this tumor entity, are effectively targetable
with the BRAF inhibitor vemurafenib,1 relapse occurs as early
as within approximately 5 months.2 Resistant tumors exhibit
upregulation of receptor tyrosine kinase receptors PDGFRB3 or
EGFR,4 signaling mediators such as CRAF or NRAS, as well as
mutations in MEK1, MEK2 and NRAS resulting in the stimulation of
the RAS/RAF/mitogen-activated protein kinase pathway (reviewed
in Spagnolo et al.2). A recent publication suggested that resistance
to vemurafenib was also dependent on the levels of nerve growth
factor receptor (NGFR, CD271) and of drug-induced nuclear factor
κB (NFκB) signaling.5,6
For therapy of melanomas lacking BRAF or other targetable
mutations, the chemotherapeutics paclitaxel, cisplatin and
dacarbacine are in clinical use, either administered in combination
or as monotherapy.7 Dacarbazine, its prodrug temozolomide,
as well as fotemustine are favorably used to treat brain metastases
because these inhibitors are capable of passing the blood–brain
barrier.8,9 Clinical trials combining these drugs with immuno-
logical or targeted therapies are ongoing.10,11
It is well known that intrinsic resistance to chemotherapeutics
involves the expression of active membrane transporters,12–14
anti-apoptotic genes,15,16 genes associated with stemness17,18 and
epigenetic modulators.17 The increased DNA repair capacity of
melanoma cells18 provides an additional mechanism conferring
intrinsic resistance to targeted drugs and chemotherapeutics.
Although chemotherapy of melanoma cells leads to acquired
resistance, DNA-damaging agents induce upregulation of DNA
damage-binding protein 2 and xeroderma pigmentosum genes.19
It has been shown that acquired resistance of melanoma and
glioblastoma to fotemustine is directly linked to high expression
of the de-alkylating enzymes.20 Thus, acquired increase of the
DNA repair capacity is likely to be a major mechanism of
melanoma cells in evading chemotherapeutic interventions
(reviewed in Soengas and Lowe21).
In view of the complexities of resistance mechanisms in
chemoresistant melanoma, it is desirable to better understand
the interplay of the determining factors and potential ways of
their regulation. Therefore, we set out to explore new factors
and regulatory mechanisms of therapy resistance by proﬁling
chemoresistant BRAF wild-type melanoma cells. In addition,
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we analyzed the consequence of drug-induced changes in gene
expression in non-resistant cells.
RESULTS
Steady-state and induced levels of CD271 protein in resistant and
sensitive melanoma cells
We performed microarray-based genome-wide expression
proﬁling of the drug-sensitive melanoma cell line MeWo
(MeWoPar) and of derivatives selected for resistance to etoposide
(MeWoEto), fotemustine (MeWoFote), vindesine (MeWoVind) or
cisplatin (MeWoCis).22 By comparative analysis of proﬁling data,
we identiﬁed subsets of genes whose elevated expression was
either common or unique to the chemoresistant cells (Figure 1a
and Supplementary Tables S1A and B). MeWoCis cells were
exceptional in that there were no marked expression alterations
compared with MeWoPar cells. Among the strongly (fold change,
FC⩾ 2, P⩽ 0.05) upregulated factors within the subset of 39 genes
common to MeWoFote and MeWoVind cells, CD271 (NGFR) attracted
our attention because of its propensity to mediate vemurafenib
resistance7 and stemness in melanoma23 (Figure 1a). We veriﬁed
the elevated transcription of CD271 by quantitative PCR (qPCR)
and upregulation at the protein level by immunoblotting
(Figure 1b). In addition, we quantiﬁed cell surface localization of
CD271 by ﬂow cytometry (Figure 1c). On average, we found
enrichment of CD271-expressing cells by a factor of 2.23 ± 0.38 in
MeWoFote, MeWoVind and MeWoEto cells, equivalent to a median
proportion of CD271-expressing cells of 62.0 ± 11.4% compared
with MeWoPar cells (27.9 ± 2.6%).
Next, we asked whether increased CD271 expression occurred
as a direct response to DNA-interfering/DNA-damaging therapeu-
tics or as a secondary effect, nonspeciﬁcally induced and
maintained during the process of selection for resistant cells. We
treated MeWoPar cells with the potent topoisomerase II inhibitor
etoposide or the mediator of DNA crosslinks cisplatin in a dosage
and time-dependent manner. Etoposide and cisplatin treatment
augmented CD271 expression in MeWoPar cells at low and high
doses, whereas MeWoEto or MeWoCis cells exhibited a constant
expression over all concentrations or showed increased CD271
only at highest dose, respectively (Figures 1d and e). Enhanced
CD271 protein levels remained elevated for 18 h after etoposide
withdrawal (Figure 1e, upper panels). This effect was more evident
in the cisplatin time course (Figure 1e, lower panels). We also
conﬁrmed upregulation of CD271 cell surface expression following
short-term treatment of MeWoPar cells with etoposide and
fotemustine but not vindesine by ﬂow cytometry. Treatment with
cisplatin showed a very similar effect on CD271 expression
(Figure 1f), suggesting transient upregulation at the protein level.
Fotemustine treatment of MeWoFote cells showed no further
increase of the CD271 level (Supplementary Figure S1A). The
dose-dependent treatment of MeWoPar or MeWoVind cells showed
only marginal or no increase of CD271, respectively
(Supplementary Figure S1B). This may suggest a direct response
of CD271 to DNA-interfering drugs, acting differently than
microtubule-interfering drugs like vindesine. Quantiﬁcation of
Ki67-positive MeWoPar cells revealed no change in response to
DNA-interfering drugs (Figure 1f, right panel).
A CD271-associated gene signature uncovers a regulatory linkage
with DNA repair
Drug resistance is associated with numerous alterations of gene
expression,24 hence we asked if CD271 can modulate drug
response by impacting on the transcriptome. To identify CD271-
responsive transcriptional targets, we performed expression
proﬁling of patient-derived melanoma cells T20/02 and the A375
cell line, both engineered to stably express CD271. Cell lines
transfected with the CD271/green ﬂuorescent protein (GFP)
transgene showed increased endogenous and ectopic
CD271 protein levels and increased cell surface localization
(Supplementary Figure S2A). Genome-wide expression proﬁling
revealed 5233 and 736 differentially regulated genes (P⩽ 0.05)
in A375NGFR/CD271 cells and T20/02NGFR/CD271 cells, respectively
(Supplementary Figures S2B and C). Of those, 235 genes were
upregulated in the two cell lines by CD271 (Figure 2a,
Supplementary Table S3). In addition, we contrasted the expres-
sion data set of T20/02NGFR/CD271 cells with those obtained after
silencing endogenous CD271 in the same cell strain.23 This
comparison identiﬁed 577 genes modulated in conjunction with
the deregulation of CD271 (Figure 2a). Among those were
340 genes transcriptionally stimulated (⩾1.5-fold) following
overexpression of CD271 (P⩽ 0.05) and downregulated (⩽0.5-fold)
by CD271 knock-down (P⩽ 0.05), (Supplementary Table S4).
In all, 237 genes followed a converse regulation, that is, were
repressed by forced CD271 expression (Supplementary
Figure S2D, Supplementary Table S5). For a deeper exploration
of proﬁling data, we performed DAVID analysis25,26 of gene
subsets and gene set enrichment analysis (GSEA)27 of the entire
data sets.
DAVID analysis of CD271-induced genes uncovered three
clusters associated with gene functions in cell cycle (enrichment
score (ES) = 1.58), DNA repair (ES = 1.34) and cell motility (ES = 1.28)
(Figure 2a, right panel and Supplementary Figure S3A). To further
investigate the association between CD271-responsive genes and
DNA repair, we performed GSEA, particularly considering a DNA
repair gene signature deposited in Broad Institute’s molecular
signature database (MSigDB, http://software.broadinstitute.org/
gsea/msigdb/index.jsp). Indeed, GSEA revealed enrichment of
genes involved in DNA repair (nominal enrichment score = 1.76) in
CD271-overexpressing cells (T20/02NGFR/CD271) and conversely
regulated in CD271 knock-down cells (T20/02k.d.) (Figure 2b).
We conﬁrmed the differential, CD271-dependent expression of
RAD21, RAD51 (homologs of S. pombe and S. cervisiae, respec-
tively), RAD51-associated protein 1 (RAD51AP1) genes, responsible
for double-strand break repair, and of DNA damage-binding
protein 2 and xeroderma pigmentosum genes involved in
nucleotide excision repair (Wiese et al.28 and reviewed in Sancar
et al.29) (Figure 2c). In A375NGFR/CD271 cells, RAD21, RAD51AP1 and
other repair genes including MSH6 (homolog of Escherichia coli
MutS) were equally upregulated in a CD271-dependent manner
(Figure 2d and Supplementary Figure S3C). To further prove the
relationship between CD271 and increased expression of repair
genes, we sorted three different patient-derived melanoma cell
strains for high endogenous and low CD271 expression by
ﬂuorescence-assisted cell sorting. The expression pattern of the
repair genes RAD21, RAD51, RAD51AP1 and MSH6 was correlated
with that of CD271 in positively and negatively sorted cells
(Figure 2e and Supplementary Figure S2E).
CD271 regulates expression of FGF13, a mediator of
chemoresistance
To further exploit the relationship between CD271 expression and
chemoresistance, we performed a supervised analysis of the
expression proﬁles of MeWoFote, MeWoVind, MeWoEto and MeWoPar
cells by GSEA based on a consensus set of 516 upregulated
CD271-responsive genes identiﬁed in T20/02NGFR/CD271 and
A375NGFR/CD271 cells (Supplementary Table S6). Compared with
MeWoPar cells, we observed enrichment of CD271-responsive
genes most evident in MeWoFote and MeWoVind, but not MeWoEto
cells (Figure 3a). We further asked for speciﬁc enrichment of genes
involved in DNA repair and cell cycle in chemoresistant cells by
using of GSEA and a subset of genes of the CD271 consensus
signature, constituting both processes. We found highest enrich-
ment of CD271-responsive genes associated with DNA damage
and cell cycle processes in MeWoFote and MeWoVind but not
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MeWoEto cells (Supplementary Figure S4A). Genes of this subset
followed a CD271-dependent regulation as validated in
engineered cells (Supplementary Figure S4A, lower panels).
In addition, GSEA led to identiﬁcation of a CD271-responsive
gene signature in MeWoFote and MeWoVind cells (Figure 3b),
comprising important components of the DNA damage repair
machinery such as PRKDC (DNA-dependent protein kinase
catalytic subunit) and RAD51 and the cisplatin resistance
associated gene encoding ﬁbroblast growth factor 13 (FGF13).30
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Figure 1. CD271 expression discriminates chemoresistant and sensitive cells. (a) Venn diagram depicts unique and commonly top
upregulated genes of resistant MeWo cells (fotemustine, MeWoFote, Fote), (vindesine, MeWoVind, Vind) or (etoposide, MeWoEto, Eto) as
compared with parental (MeWoPar, Par). (b) Left panel: veriﬁcation of CD271 expression in resistant cells by qPCR, shown are relative
expression levels± s.d. of independent triplicates. Right panels: immunoblot analysis of cells described in a, cisplatin resistant (MeWoCis, Cis),
as well as parental cells for levels of CD271. (c) Comparative ﬂow cytometry analysis of resistant and parental MeWo cells for levels of CD271.
(d, e) Immunoblot analysis of MeWoPar, MeWoEto and MeWoCis cells following a dose (etoposide: 0.1–10 μM and cisplatin: 0.3–30 μM both 24 h)
and time dependent (2, 4, 6 and 24 h, *etoposide or cisplatin was withdrawn after 6 h, cells were maintained for additional 18 h) treatment for
levels of CD271. (f) Left panels: analysis of MeWoPar cells following treatment with either etoposide (10 μM), cisplatin (10 μM), fotemustine
(30 μg/ml) or vindesine 1 ng/ml for 24 h for cell surface expression of CD271. Right panel: quantiﬁcation of Ki67-positive MeWoPar
cells following drug treatment for 24 h. Shown are numbers of Ki67-positive cells in %± s.d. related to 4′,6-diamidin-2-phenylindol (DAPI).
In (b, d, e), whole-cell lysates were analyzed, β-tubulin served as loading control; in (c, f) 10 000 cells were recorded following incubation with
either CD271-PE (top panels) or mouse IgG1 isotype control (mIgG1, lower panels). Shown are mean values± s.d. as indicated.
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(Figure 3c) and found a remarkable (250-fold) downregulation
upon silencing of CD271 in those cells (MeWoFote-shCD271)
(Figure 3c, right panel). In addition, MeWoPar engineered cells to
overexpress CD271 (MeWoPar-NGFR/CD271) showed increased levels
of FGF13 mRNA, suggesting a CD271-dependent expression of
FGF13 (Figures 3d and e). Finally, we asked whether forced
expression of CD271 in MeWoPar cells renders them refractory to
cisplatin. We observed that overexpression of CD271 (NGFR)
indeed signiﬁcantly decreased the sensitivity of parental MeWo
cells to cisplatin but not to fotemustine, etoposide or vindesine
(Figure 3f and Supplementary Figures S4B and D) as compared
with GFP-expressing (MeWoPar-GFP) or non-transfected (Par)
control cells.
Knock-down of CD271 partially restores drug response in
fotemustine-resistant cells
To investigate a causal role of CD271 in chemoresistance,
we stably knocked-down CD271 expression in MeWoFote cells
(MeWoFote-shCD271, Figure 3c right panel and Supplementary
Figure S5A). CD271 silencing induced moderate morphological
changes of cells grown in monolayers but no signiﬁcant inhibition
of proliferation as determined by counting of Ki67-positive
Figure 2. Integrative analysis of melanoma cells with overexpression and/or knock-down of CD271 links CD271 with DNA repair. (a) Venn
diagram depicting commonly upregulated genes induced in A375 and T20/02 cells engineered to stably express CD271 (A375NGFR/CD271,
T20/02NGFR/CD271) or stably transfected with a CD271-targeting shRNA (shCD271, T20/02k.d.). Numbers of identiﬁed genes found commonly
upregulated in A375NGFR/CD271 and T20/02NGFR/CD271 (235 genes) or differentially regulated in T20/02NGFR/CD271 and T20/02k.d. cells (577 genes,
comprising up and downregulated genes) are shown. Right panel: DNA repair cluster from DAVID analysis of a set of 340 CD271-responsive
genes upregulated in T20/02 cells, red or blue indicates positive or negative GO-contribution, respectively. (b) GSEA of proﬁling data
of T20/02NGFR/CD271 and T20/02k.d. cells using a DNA repair signature (230 genes) as provided by MSigDB.18 (c) Veriﬁcation of the
CD271-dependent regulation of DNA repair genes RAD21, RAD51, RAD51AP1, DNA damage-binding protein 2 (DDB2) and xeroderma
pigmentosum genes (XPC) in T20/02NGFR/CD271 (left panel) or cells stably transfected with CD271 speciﬁc shRNAs (#2, #3, #4) by qPCR
(right panel). Expression levels are shown in logarithmic scale, indicating relative expression levels± s.d. of independent triplicates, compared
with cells either expressing GFP or knock-down control (shCtl.). *P⩽ 0.05; **P⩽ 0.01; ***P⩽ 0.001. (d) CD271-induced expression of DNA repair
genes in A375NGFR/CD271 cells as determined by qPCR. (e) Expression levels of CD271, RAD51AP1, RAD51 and MSH6 in cells of patient-tumor
derived cell strains (Mel91, T20/02 and Mel41) sorted for presence or absence of CD271 by ﬂuorescence-assisted cell sorting (FACS). Shown are
three independent experiments.
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cells (Figure 4a). Next, we assessed the susceptibility of CD271
knock-down cells to fotemustine. In MeWoFote-shCD271 cells (clones
shCD271_5-2 and shCD271_5-1), the susceptibility to fotemustine
was partially restored as indicated by reduced viability of clone 5-2
at 100 μg/ml (76.9 ± 2.6% vs 109.9 ± 10.1%) and clone 5-1 at
300 μg/ml (47.5 ± 11.5% vs 78.6 ± 7.1%), as well as by enhanced
apoptosis following 48-h treatment (Figure 4b). In addition,
we explored the response of clone 5-1 to cisplatin, vindesine
and etoposide and observed that none of these showed
a comparable response as compared with fotemustine
(Supplementary Figure S5B). Moreover, we performed a stable
knock-down of CD271 in MeWoVind cells, by two independent
short hairpin RNAs (shRNAs; sh#3, sh#4) yielding in a robust
downregulation of CD271 (Figure 4c and Supplementary
Figure S5C, left panel). However, knock-down of CD271 did not
sensitize cells to vindesine, etoposide or cisplatin (Figure 4c,
Supplementary Figure S5C and data not shown) but at least partly
increased the response to fotemustine (Figure 4c, right panel).
CD271-responsive genes confer a metastatic phenotype on
melanoma cells
As selective pressure occurring upon drug-based therapies can
lead to changes in expression levels of genes favoring metastasis
and relapse,31,32 we asked whether expression of CD271 and its
responsive genes may be involved in mediating a migratory/
metastatic phenotype. We took advantage of a life cell imaging
system based wound-healing assay, which allowed us to monitor
migration of A375NGFR/CD271 and MeWoPar-NGFR/CD271 and control
cells (A375GFP, MeWoPar-GFP) within 2 days. We observed that
overexpression of CD271 in A375 and MeWo cells speciﬁcally
increased the migratory phenotype and accelerated wound
closure in both cellular systems (Figure 5a, Supplementary
Figure S6A and Supplementary Movie Files 1–4). In addition,
we observed that MeWoVind and MeWoFote cells showed a 3.9-fold
and 1.2-fold increased migration as compared with MeWoPar cells
(Supplementary Figures S6B and C and Supplementary Movie Files
5 and 6).
Figure 3. CD271-responsive genes are predominantly expressed in chemoresistant cells. (a) GSEA with proﬁling data of MeWoFote, MeWoVind
and MeWoEto cells and a consensus signature, comprising 516 CD271-responsive genes. FDR, false discovery rate; NES, nominal enrichment
score; NS, no signiﬁcant enrichment. (b) Venn diagram depicting commonly found CD271-responsive genes in chemoresistant cells. FGF13
represents the most common gene in MeWoFote and MeWoVind cells. (c) Left panel: qPCR of MeWoFote and MeWoPar cells and right panel:
MeWoFote cells stably transfected with a validated CD271-targeting shRNA (shCD271) or control (shCtl.) for expression of CD271 and FGF13.
(d) Immunoblot analysis of whole-cell lysates of MeWoPar cells either non-transfected (Mock) or engineered to stably express CD271 (NGFR,
GFP-tagged) for levels of CD271. (e) Expression level of FGF13 in MeWoPar cells either stably or transiently expressing CD271. (f) Determination
of viability of MeWoCis (Cis) and MeWoFote (Fote) cells as compared with stably GFP (Par-GFP) or NGFR/CD271-expressing MeWoPar (Par-NGFR)
cells following a dose-dependent treatment with either cisplatin (μM) or fotemustine (μg/ml). Viability is indicated in %± s.d. of n= 8 technical
replicates. A representative out of n= 3 biological replicates is shown.
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Using GSEA, we recovered the metastasis and relapse gene
signature of Broad Institutes’ MSigDB within the data sets of
A375NGFR/CD271 and T20/02NGFR/CD271 cells (Figures 5b and c and
Supplementary Figure S7A). The CD271-responsive genes
RAD51AP1 and the known resistance mediators NIMA-related
kinase 2 (NEK2)33 and Hyaluronan-mediated motility receptor
(HMMR),34 as well as topoisomerase II were highly expressed in
MeWoFote cells (Figure 5d, left panel and data not shown). The
CD271-dependent upregulation of NEK2, HMMR and TOP2A
observed by GSEA was validated (Figure 5d, center and right
panel and Figure 2d). To further assess whether expression of
CD271-responsive genes may not only promote chemoresistance
but also metastasis formation, we took advantage of publicly
available expression proﬁling data of primary (n= 31) and
Figure 4. Levels of CD271 expression modulate drug response. (a) Left panels: IF microscopy of MeWoFote cells stably transfected with a
validated CD271-targeting shRNA (shCD271_5-2, clone 5-2) or control (shCtl.) for CD271 (red, left panels), phalloidin (red, center panels),
presence of Ki67 (green, right panels) or bright ﬁeld is shown. Numbers represent % of Ki67-positive cells± s.d. of n= 4 counts related to
4′,6-diamidin-2-phenylindol (DAPI) that served as nuclear stain, scale bars indicate 50 μm. Right panel: IF microscopy of clone 5-1
(shCD271_5-1) for phalloidin or bright ﬁeld is shown. (b) Left and right panels: determination of cell viability and apoptosis of MeWoFote cells,
clone 5-2/clone 5-1 modiﬁed as described in a following a dose-dependent treatment with fotemustine (μg/ml) for 48 h. Viability is indicated
in %± s.d. of n= 8 replicates, related to untreated (100% viability) cells, a representative out of three biological replicates is shown,
UT=untreated; 0= solvent control. Apoptosis was determined by an ELISA-based measurement of apoptosis induced DNA-fragmentation of
clone 5-2 and clone 5-1 after 48 h, scales indicate apoptosis as OD405 values, *P⩽ 0.05; **P⩽ 0.01; ***P⩽ 0.001. (c) Left panels: IF microscopy of
MeWoVind cells following stable knock-down of CD271 by a validated shRNA (sh#4) for levels of CD271 (red), Ki67 (green) or bright ﬁeld. Center
and right panel: determination of cell viability CD271 knock-down cells (pool) following a dose-dependent treatment with vindensine and
fotemustine for 48 h. Representative experiments out of n= 3 are shown.
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Figure 5. Expression of CD271-responsive genes facilitates discrimination of primary tumor and melanoma metastases. (a) Left panels:
migratory capacity of A375 cells stably transfected with either GFP or CD271 (NGFR/CD271, GFP positive) at time points 0, 7, 15 and 19 h after
wounding. Wound closure is indicated by an increasing migration front (blue) and a decreasing wound area (yellow). Right panel:
quantiﬁcation of wound closure. Shown are average wound widths (μm) of n= 8 replicates relative to time of imaging (h) of GFP (black) or
NGFR (red) transfected cells. Scale bars indicate 200 μm. (b, c) GSEA of proﬁling data of A375NGFR/CD271 or T20/02NGFR/CD271 or T20/02k.d. cells
and signatures indicating melanoma metastasis46 or melanoma relapse.18 Top enriched genes are indicated. (d) Expression levels of potential
mediators of drug resistance NEK2, HMMR and RAD51AP1 in MeWoFote cells as compared with MeWoPar. Center and right panel: validation of a
CD271-dependent expression of NEK2 and HMMR or NEK2 in T20/02NGFR/CD271 or A375NGFR/CD271 cells, respectively. (e) Venn diagram
depicting overlapping genes found among data sets of melanoma metastasis (1054 genes) of study GSE8401 as provided by the GEO
database and CD271-responsive genes identiﬁed in T20/02 cells (340 genes). (f) Supervised clustering of selected CD271-regulated genes
depicting distribution in a set of primary tumors and melanoma metastasis. Tumor site is color coded. (g) Expression levels of known ligands
potentially binding to CD271, for example, NGF, brain-derived neurotrophic factor (BDNF) and neurotrophin 4 (NTF4) in MeWoPar cells
following treated with fotemustine (30, 100 μg/ml) for 24 h (left and center panels) as determined by qPCR. In (d, g), scales indicate relative
expression levels± s.d. of independent triplicates, *P⩽ 0.05; **P⩽ 0.01; ***P⩽ 0.001.
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metastatic melanoma (n= 52).35 Exploration of the set of
upregulated genes (n= 1054, 42-fold, P⩽ 0.05) revealed the
presence of 110 CD271-responsive genes, upregulated in
melanoma metastases (Figure 5e and Supplementary Table S7).
Among them, we found NEK2, RAD51AP1 and LYPD1
(LY6/PLAUR domain containing 1), a neuronal transmembrane
protein potentially associated with brain metastases.36 Statistical
analysis revealed that expression of the CD271-responsive
genes NEK2 (P= 1.56E–06), RAD51AP1 (P= 2.67E–04), HMMR
(P= 5.47E–07) and TOP2A (P= 1.56E–06) but not FGF13
(P= 0.3122) signiﬁcantly discriminated primary tumors and
melanoma metastases (Figure 5f and Supplementary Figures S7B
Figure 6. Mechanistic insights in the regulation of CD271. (a) Immunoblot analysis of MeWoPar cells treated with either cisplatin (Cis),
etoposide (Eto) or temozolomide (TMZ) (all at a ﬁnal concentration of 10 μM) for levels of CD271 (s/l= short/long exposure), p-p53S15, p21CIP,
γH2AX, p-ERK1/2 and ERK1/2, p-AKTS473 and AKT, p-IκBα, p-CHK1 and p-p38 kinase. (b) Immunoblot analysis of MeWoEto, MeWoCis or MeWoPar
cells following dose-dependent treatment with etoposide or cisplatin (3, 10 μM both) for 24 h, respectively. Levels of CD271, γH2AX and
phosphorylated (activated) p53 (p-p53S15) are shown indicating the different response of sensitive and resistant cells to drugs. (c) Regulation
of p53-targets MDM2, p21CIP (CDKN1A), CD95, NOXA, XIAP, as well as MSH6 and CD271 in MeWoPar and MeWoEto cells treated with etoposide
(3, 10 μM) for 24 h. Shown are relative expression levels of representative experiments (I, II). (d) Immunoblot analysis of T20/02 cells stably
transfected with shCD271 or control, following dose-dependent treatment with etoposide for levels of CD271, p-p53S15, p21CIP and γH2AX.
(e) Analysis of cells described in d but stably transfected with different CD271-targeting shRNAs (sh#2, sh#3, sh#4) or control (shCtl.) for levels
of p53, p21CIP, CD95, NOXA and BAX. Scale indicates relative expression levels± s.d. of independent triplicates, *P⩽ 0.05; **P⩽ 0.01;
***P⩽ 0.001. In (a, b, d), whole-cell lysates were analyzed, β-tubulin served as loading control. (f) Panel-based next-generation sequencing
(NGS) revealed detection of a TP53 mutation (p.E258K, 5′-GAA-4AAA-3’; antisense (3′-CTT→ TTT-5′)) in MeWoPar cells, not present in wild-type
T20/02 cells. Shown are sequences, as well as read depths. (g) Left panel: immunoblot analysis of cells described in d for levels of CD271 and
p21CIP following a dose-dependent treatment with MDM2 inhibitor nutlin-3a. Right panel: nutlin-3a treatment of MeWoPar cells.
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and C). A predominant expression of RAD51AP1 was in addition
observed in a small set of brain metastases (Supplementary
Figure S7D).37 Keratin 17 was found inversely correlated with
expression of CD271-responsive genes in melanoma metastases
(Figure 5f), upregulated upon CD271 knock-down (data not
shown). The role of CD271 as mediator of melanoma metastasis
is further underpinned by the inverse regulation of the known
suppressor of melanoma metastasis KISS138 and DMBT1 (deleted
in brain tumors 1). DMBT1 expression is frequently lost in lung
cancer39 and glioblastoma.40 We observed a strong upregulation
of both genes upon knock-down of CD271 in MeWo derivatives
and T20/02 cells (Supplementary Figures S6D and E), suggesting
that CD271 expression leads to repression of both metastasis
inhibitors, facilitating melanoma metastasis.
As we identiﬁed mediators of melanoma metastasis among
CD271-responsive genes, we next asked whether these genes
can be induced in MeWoPar cells by fotemustine treatment.
We observed increased expression of NEK2 and RAD51AP1
(Supplementary Figure S7E, left panel) as well as strong increased
levels of the ligands of CD271, nerve growth factor (NGF,
~ 13.5-fold) and neurotrophin 4 (~3.5-fold) (Figure 5g) following
fotemustine treatment for 24 h. Brain-derived neurotrophic factor
was only marginally increased, melanoma antigen recognized by
T cells 1 showed inverse correlation with CD271 and neurotro-
phins. In conclusion, the enhanced expression of neurotrophins
like NGF upon drug treatment and in drug-resistant cells
(MeWoFote) (Supplementary Figure S7E, right panel) suggests that
the genetic programs governing drug resistance and metastasis
may overlap at least partially.
CD271 is induced in a p53-dependent manner
To assess the mechanisms regulating the drug-mediated induc-
tion of CD271, we explored signaling processes potentially
induced on drug treatment of MeWoPar cells. Pathway compo-
nents included stabilized p53 (p-p53S15), p21CIP (CDKN1A),
mitogen-activated protein kinase (extracellular signal-regulated
kinases 1 and 2 (ERK1/2), p38 kinase), AKT signaling as well as
checkpoint-kinase 1 (CHK1), a direct target of ataxia telangiectasia
mutated and ataxia telangiectasia and RAD3-related signaling. The
latter is the DNA damage sensor pathway and marks sites of DNA
damage via formation of γH2AX a crucial step initiating DNA
repair.29 We also determined phosphorylation of IκBα and the
nuclear localization of NFκB/p65, as activation of NFκB signaling
was earlier recognized as a proposed mechanism of CD271
regulation.7
We observed a strong activation of mitogen-activated protein
kinase signaling (p-ERK1/2) and the p53-signaling pathway
following treatment with cisplatin (Cis), etoposide (Eto) or
temozolomide, as well as a moderate activation of p38 kinase
and CHK1 (Figure 6a), however, we did not detect activation of
canonical NFκB signaling (Figure 6a and Supplementary
Figure S8A). In contrast to MeWoPar cells, p53 was not stabilized
in chemoresistant MeWoEto and MeWoCis cells upon drug
treatment (Figure 6b). Moreover, known p53 targets41 and
CD271 were co-regulated in etoposide-treated MeWoPar but not
in MeWoEto cells (Figure 6c), supporting the conclusion that the
p53 pathway is impaired in resistant cells. We observed a lower
induction of p53 targets upon treatment with cisplatin in MeWoPar
cells as compared with etoposide and also observed a weak
regulation of targets in MeWoCis cells (Supplementary Figure S8B).
To further assess the connection between p53 and CD271, we
investigated the response of the p53 pathway in a patient-derived
cell strain following stable knock-down of CD271 and dose-
dependent treatment with etoposide. Etoposide treatment
increased levels of γH2AX, p-p53S15 and p21CIP in control cells
but not in CD271 knock-down cells (Figure 6d). The levels of p53
itself, of p53 targets, as well as of the DNA damage sensors PRKDC,
Nijmegen breakage syndrome 1 and ataxia telangiectasia mutated
were downregulated in CD271 knock-down cells. Expression of
ataxia telangiectasia and RAD3-related was not affected (Figure 6e
and Supplementary Figure S9A). In line with downregulation of
DNA repair genes, knock-down cells showed increased DNA
damage (Supplementary Figure S9A, center and right panels).
These data suggest that endogenous levels of CD271 are required
for proper drug response. We observed comparable CD271-
dependent regulations of p53 targets and sensors of DNA damage
repair in MeWoFote and MeWoVind cells upon knock-down of
CD271 albeit with lower signiﬁcance (Supplementary Figures S9A
and B).
The co-regulation of p53 and CD271 in drug-exposed MeWoPar
cells may suggest that CD271 upregulation is controlled by p53.
The CD271 promoter harbors three potential binding sites
matching the consensus sequence of p53 as predicted
by p53FamTaG algorithm (http://p53famtag.ba.itb.cnr.it/)
(Supplementary Figure S10A). To elucidate, if p53 indeed controls
CD271 expression, we treated T20/02 and MeWoPar cells with the
MDM2 inhibitor nutlin-3a, which stabilizes p53 leading to
activation of downstream signaling, in p53 wild-type cells.
Panel-based next-generation sequencing of MeWoPar, resistant
derivatives and T20/02 cells revealed the presence of a TP53
p.E258K mutation in MeWoPar and resistant cell lines and
evidenced the wild-type status of T20/02 cells (Figure 6e,
Supplementary Figure S10B and Supplementary Table S2A). In
line with this observation, we observed a strong increase in p21CIP
but not CD271 in T20/02 (shCtl.) but not CD271 knock-down
(sh#3) or MeWoPar cells (Figure 6f). These data suggest that knock-
down of CD271 impairs activation of p53-dependent signaling
processes by inhibition of MDM2 as well as DNA-damaging drugs.
In addition, qPCR and immunoﬂuorescence (IF) microscopy
showed comparably low levels of mutant p53 in all MeWo
derivatives (Supplementary Figures S10C and D). Further,
next-generation sequencing and copy number analysis revealed
the presence of a mutation (p.I2018F) or ampliﬁcation of PRKDC
in MeWoCis or MeWoFote cells (Supplementary Figure S10E),
respectively. Mutations in additional genes involved in DNA
repair, for example, Fanconi Anemia Complementation Group A
(FANCA) found in MeWoFote cells or ampliﬁcation of Meiotic
Recombination 11 Homolog A (MRE11A) observed in MeWoVind
cells (Supplementary Figure S10E) may render cells susceptible to
drugs by increased genomic instability.
DISCUSSION
Stem cell-like properties are considered as a major cause for
rendering cancer cells intrinsically resistant to therapeutics.42,43
NGFR (tumor necrosis factor superfamily member 16 or CD271)
has been used as a marker to enrich for tumor-initiating cells in
melanoma.44 Our own previous ﬁndings had indicated that CD271
not only regulates stem cell functions, for example, tumorigenicity
and plasticity, but was also highly expressed in patient-derived cell
cultures from melanoma metastases.23 These results prompted
the current investigation as to whether CD271 was involved in
chemoresistance, particularly in wild-type BRAF melanomas not
eligible for anti-BRAF kinase therapy. We show here that selection
of MeWo cells for acquired resistance to chemotherapeutics
triggering DNA damage via alkylation, cross-linking of DNA or
topoisomerase inhibition was accompanied by high CD271
expression. High expression of CD271 was maintained in resistant
cells, with exception of MeWoCis cells, which may have developed
a different mechanism to overcome cisplatin-induced DNA
damage without the need for CD271. However, short-term
exposure of drug-sensitive cells to chemotherapeutics induced
CD271 expression already after 4 h, suggesting that CD271
upregulation and drug exposure were directly linked rather than
due to selection of highly expressing cells present in a
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heterogeneous cell population. Moreover, silencing of CD271
partially re-sensitized resistant cells toward drug treatment and
identiﬁed a link between enhanced CD271 expression and the
regulation of FGF13, a known mediator of cisplatin resistance.30
Upregulation of CD271 in response to drugs occurred in a
p53-dependent manner. However, the relationship between
CD271 and p53 appeared to be more complex and additional
general mechanisms involved in stress response45 may trigger
CD271 expression. In drug-sensitive melanoma cells, in which
intrinsically moderate CD271 expression was silenced by intro-
duction of shRNA, the p53-dependent DNA repair system was
impaired because of low expression or activation of p53 and of
crucial proteins acting as DNA damage sensors PRKDC, Nijmegen
breakage syndrome 1 and ataxia telangiectasia mutated. This
suggested that a sufﬁcient level of CD271 in turn is required for
the proper response of cells to chemotherapeutic drugs. This
conclusion is based on the results of gene expression proﬁling of
cells in which CD271 was either silenced or enhanced by ectopic
expression of a recombinant CD271 expression vector. CD271-
related gene signatures comprised predominantly DNA repair
genes, cell cycle progression genes and genes involved in
metastasis. This may explain why DNA repair genes are expressed
at a higher level in CD271-expressing chemoresistant melanoma
cells in the absence of p53 expression levels exceeding those in
drug-sensitive cells. However, a CD271-independent upregulation
of the DNA repair machinery cannot be excluded at this stage.
Figure 7. Proposed model for the CD271 regulation and potential downstream effects mediating drug resistance and metastasis. (a) Alkylating
drugs (fotemustine, TMZ), TOP2A inhibitors (etoposide) or inter-cross-linking agents (cisplatin) induce expression of CD271 in MeWoPar cells.
(b) Drug-dependent DNA damage results in activation of the ataxia telangiectasia mutated (ATM)/ataxia telangiectasia and RAD3-related (ATR)
pathway leading to formation of stabilized p53 (p-p53S15) and γH2AX. Stabilized p53 may regulate expression of CD271. (c) Phenotypic
consequences associated with increased CD271 expression levels. Left: drug-sensitive cell population (CD271 low), middle: Short-term drug
treatment of sensitive cell population (CD271 intermediate), right: drug-resistant cell population (CD271 high), prone to metastasis. (d) Left:
Downstream consequences of enhanced CD271/NGFR expression by drug treatment or overexpression (NGFR-GFP). Right: sustained
expression of CD271 regulating drug resistance (FGF13, TOP2A, NEK2) and metastasis-associated (RAD51AP1, TOP2A) genes.
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Moreover, although our survey points out a role of CD271 in
drug resistance, we only observed a partial sensitization of
MeWoFote or MeWoVind cells to certain drugs. In addition,
overexpression of CD271 was unable to fully mimic the resistant
phenotype of observed in any of the resistant cells lines. This
suggests that additional mechanisms are present in chemo-
resistant melanoma cells and clonal heterogeneity supposedly
lead to variabilities in drug response.
Besides DNA repair genes, ectopic CD271 expression impinged on
target genes, which have previously been associated with
melanoma relapse and metastasis.18,46 Our survey of potential
CD271-associated genes in publicly available melanoma expression
proﬁles recovered as many as 110 CD271-responsive genes
predominantly expressed in metastases, among them the NEK2
gene (Never in mitosis gene A-related kinase 2), previously found
associated with drug resistance in myeloma33 and RAD51AP1
previously associated with metastasis of melanoma and breast
cancer18,47 as well as TOP2A (topoisomerase II). Expression of TOP2A
was associated with worse prognosis in melanoma.48 NEK2 was also
identiﬁed as a regulator of aldehyde dehydrogenase 1, a marker of
cancer-initiating cells,49 again linking stem cell function and drug
resistance. A hypothetical model depicting the regulation of CD271
and downstream effects is shown in Figures 7a-d.
Metastasis to the brain is frequently observed in melanoma
patients, therapeutically treated with drugs able to pass the
blood–brain barrier, such as fotemustine, temozolomide or
dacarbacine. Recent publications demonstrated that expression
of CD271 is frequently observed in melanoma brain metastases.50
These ﬁndings are in line with our observation deﬁning a crucial
role of CD271 in regulating metastasis gene expression and
conferring chemoresistance. Moreover, CD271 expression was
found in brain metastatic melanoma cells resistant to
vemurafenib.8 These observations underpin our ﬁnding that
CD271-responsive genes were also predominantly expressed in
a small set of matched melanoma brain metastases. Notably, NGF
mediates melanoma cell migration and metastasis as reported
previously.51
High expression of metastasis-associated CD271-responsive
genes NEK2, RAD51AP1, TOP2A and NGF in drug-resistant
MeWo cells and their drug-dependent regulation, may have
consequences for the priming of melanoma cells for metastasis.
Although FGF13 shows no statistical signiﬁcant discrimination
between melanoma primary tumors and metastases, we observed
that subsets of melanoma metastases show high expression of
either FGF13 or LYPD1. The role of both genes are poorly
understood in melanoma metastases, however, FGF13, which is a
special type of FGFs, is not only associated with signaling
processes but also has a role in microtubule stabilization and
the regulation of neuronal polarization and migration.52 Hence,
FGF13 may present a new driver of melanoma metastasis.
In general, these ﬁndings lead to the provocative hypothesis
that sustained expression of CD271 may activate a genetic
program promoting simultaneously drug resistance and
metastasis. CD271-expressing cells potentially start to metastasize
earlier than CD271-negative cells. This is further underpinned by a
very recent work53 and our observation that melanoma cells with
a high endogenous level or overexpression of CD271 showed
increased migration into a scratch wound, suggesting CD271 as a




All primary low passage melanoma cell strains, as well as their derivatives
were cultured in Quantum 263 tumor growth medium (Q236, Capricorn
Scientiﬁc, Marburg, Germany) supplemented with 1% penicillin/strepto-
mycin (Invitrogen, Carlsbad, CA, USA). The patient tumor-derived cell strain
T20/02 has been established from a lymph node metastasis. A375 cells
(ATCC, Manassas, VA, USA) and MeWo cell lines were cultured in Leibovitz's
L-15 medium (Invitrogen) supplemented with 10% fetal bovine serum, 1%,
penicillin/streptomycin (Invitrogen), transferrin/fetuin, minimum essential
medium-vitamins, insulin, glucose and sodium bicarbonate. Next-
generation sequencing of T20/02 and MeWo cells revealed absence of
mutations in BRAF or RAS (K/H/N), Supplementary Table S2A. Cells were
cultured in 5% CO2, 37 °C and routinely passaged at 80% conﬂuence.
Medium was changed every 3 days. Stably shRNA or control transfected
fotemustine-resistant cells were selected for puromycine resistance (10 μg/
ml) and sub-cloned by limited dilution assays, which yielded in clones 5-1
and 5-2. Vindesine resistant cells were transfected with shRNA or control
plasmids, selected for generation of cell pools.
Drug treatment assays
Drug treatments were performed for at least 48 h in six-well plates
(2.5 × 105 cells seeded) for RNA/protein extraction or 96-well plates (2500
cells per well seeded) for viability assays. Stock solutions of etoposide
(10 mM, dimethylsulfoxide), cisplatin (1670 mM, sodium chloride, 0.9%),
temozolomide (10 mM, dimethylsulfoxide) and nutlin-3a (10 mM, dimethyl-
sulfoxide), (all from Sigma-Aldrich, Munich, Germany) and fotemustine
(50 mg/ml, ethanol, 80%) were used. Fotemustine was received either
directly from the hospital and administered to cells at day of preparation,
or received from company (Sigma-Aldrich). Viability was determined by
MTT assay using 50 μl of MTT solution (5 mg/ml) added 48 h after drug
treatment. Concentration of dimethylsulfoxide-solubilized formazan was
detected at 570 nm after 1 h of incubation.
Flow cytometry/ﬂuorescence-assisted cell sorting
Fluorescence-assisted cell sorting and ﬂow cytometry were performed
as reported previously.23 Data analysis was done with FlowJo software
(http://www.ﬂowjo.com/).
Immunoblot
Total cell lysates were prepared in sodium dodecyl sulfate lysis buffer
(1% sodium dodecyl sulfate, 10 mM Tris-HCl, 2 mM EDTA). In all, 10–25 μg of
whole-cell lysates were separated on 12% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis gels and transferred on a nitrocellulose
membrane by using the iBlot Dry Blotting System (Invitrogen). Membranes
were blocked with Odyssey Blocking Buffer/phosphate-buffered saline-
Tween (0.1%), (1:1, LI-COR Biosciences, Lincoln, NE, USA) for 1 h. Incubation
with primary antibodies (p75NTR clone D4B3XP recognizing the total
CD271, p-ERK1/2, ERK1/2, p-AKT(S473), AKT, γH2AX, p21CIP, p-p53(S15),
p-IĸBα, p-p38, p-Chk1 and β-tubulin, clone 9F3; all 1:1000; from Cell
Signaling Technology, New England Biolabs GmbH, Frankfurt am Main,
Germany) was done overnight at 4 °C. Incubation with secondary
antibodies donkey anti-rabbit immunoglobulin G or donkey anti-mouse
both (diluted 1:10 000; LI-COR Biosciences) was done for 1 h at room
temperature. Signals were detected with the Odyssey Infrared Imaging
System (LI-COR Biosciences).
RNA isolation and quantitative reverse transcriptase–PCR
RNA isolation was performed as reported previously.23 Primers were
designed using the PrimerQuest Tool (http://eu.idtdna.com/ primerquest/
home/index) for 55–60 °C annealing temperatures and product size of
100–250 bp (Supplementary Table S8).
Immunoﬂuorescence
IF was performed as reported previously.23 Incubation with primary
antibodies CD271-PE (Miltenyi, Bergisch Gladbach, Germany, clone ME20.4-
1.H4, mouse IgG1, 1:100), γH2AX (1:250, Cell Signaling Technology), NFκB/
p65 and p53 (Cell Signaling Technology, 1:100) or TRITC-labeled phalloidin
(1:1000, Sigma-Aldrich) diluted in blocking buffer was done overnight at 4 °
C. Second day, cells were washed 3x with phosphate-buffered saline, and
incubated with secondary antibodies AlexaFluor488/555 or 594 (1:500)
recognizing either rabbit or mouse-produced antibodies and 4′,6-diamidin-
2-phenylindol (Sigma-Aldrich, 1:500) for 1 h at room temperature. Washed
cells were covered with 500 μl phosphate-buffered saline and used for
microscopy. IF pictures were recorded with Zeiss Axiovert40CFL with
accompanied Illuminator HPX120C and software AxioVision Rel. 4.8 (all Carl
Zeiss AG, Oberkochen, Germany).
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Live cell imaging-based cell migration assay
Migration of model cell lines overexpressing CD271 (A375NGFR/CD271;
MeWoPar-NGFR/CD271) or controls (A375GFP; MeWoPar-GFP), as well as
fotemustine or vindesine resistant cells (MeWoFote; MeWoVind) was
performed with the scratch wound cell migration assay (Essen Bioscience
Ltd, Welwyn Garden City, Hertfordshire, UK) following the manufacturer’s
instructions. Brieﬂy, 30 000 cells of each cell line were seeded 24 h before,
yielding in a dense cell layer. Reproducibly wounds were scratched with
the Wound Maker, a block with 96 pins. After wounding, the 96-well plate
was placed into the Incucyte ZOOM life-cell imaging system (Essen
Bioscience Ltd.). Cell migration was monitored every 2 h for 2 days, using a
× 10 magniﬁcation. Serial pictures were stacked for movie preparation
using the ImageJ software (https://imagej.nih.gov/ij/). Statistical analysis
was performed by using a two-tailed, paired t-test.
Generation of stable cell lines
Knock-down of CD271 was performed as reported previously.23 For
overexpression, melanoma cells were stably transfected with a plasmid
expressing GFP-tagged human NGFR (RG207966, OriGene, Rockville, MD,
USA) and selected with G418 (100–300 μg/ml, PAA). Stable GFP-expressing
control cell lines were established by viral transduction with pLenti-PGK-
GFP (Addgene, Cambridge, MA, USA). Brieﬂy, 5 × 106 293LTV (BIOCAT
GmbH, Heidelberg, Germany) were transfected with 4.5 μg pLenti-PGK-GFP
plasmid and 4.5 μg packaging plasmid (pLenti Combo Mix I, HIV Lentiviral
Packaging Plasmid Mix, BIOCAT) using calcium chloride precipitation. Virus
containing supernatant was collected 48 h after transfection and
concentrated (~50-fold) using PEG-it solution (SBI, Palo Alto, CA, USA).
Gene expression proﬁling
Whole-genome expression proﬁling of chemoresistant and sensitive
melanoma cells (MeWo, GSE78898) or cells of a patient-derived cell strain
(T20/02) stably transfected either with a CD271-targeting (T20/02k.d.) or a
control shRNA (GSE52456) plasmid, as well as T20/02 and A375 cells stably
expressing either NGFR/CD271 or GFP (GSE78155) was performed with
three biological replicates. Gene expression of parental (n=1) and
chemoresistant derivatives (Eto, Fote n= 3; Vind, Cis n=2) was measured
on two Illumina BeadChips (HumanHT-12V4, Illumina Inc., San Diego, CA,
USA). After summarization via BeadStudio, data on each chip was quantile
normalized (R package preprocessCore) and ﬁltered (detection Po0.01 for
at least one sample). After combination of chips by quantile normalization
and batch correction (R package sva), signiﬁcance thresholds for
differential regulation were set to mean FC⩾ 2 and adjusted P-value
o0.05 (R package limma). Plots and heat maps were generated using R
packages ggplot2 and heatmap.3 with spearman's rank correlation as
similarity measure and complete linkage.
Gene set enrichment analysis
GSEA was performed with appropriate software (GSEA version 2.2.2,
Cambridge, MA, USA), as well as signatures speciﬁc for DNA repair,
melanoma relapse and melanoma metastasis were received from the latest
version of the Molecular Signatures Database v5.1 (MSigDB, GSEA) of the
Broad Institute (http://software.broadinstitute.org/gsea/ downloads.jsp).
The CD271-responsive gene signature represents a consensus (n= 516
genes) of genes upregulated in A375NGFR/CD271 and/or T20/02NGFR/CD271
cells. DAVID analysis was used to derive a sub-signature (n= 187 genes)
from the consensus signature comprising genes associated with DNA
repair and cell cycle processes.
Meta-analysis
Exploration for presence of CD271-responsive genes, publicly available
data were used comprising primary melanoma with melanoma metastases
of different organs (GSE8401) or extracranial with brain metastases
(GSE50496). From the latter study, only matched pairs of extracranial
and brain metastases were taken into consideration for analysis. Data were
downloaded from GEO (http://www.ncbi.nlm.nih.gov/geo). Statistical
analysis of CD271-responsive genes differentially expressed among
melanoma metastases and primary melanoma was done in R using a
modiﬁed version of the linear model function (lm).
Panel-based sequencing and copy number variation (CNV)
Panel-based next-generation sequencing was performed following the
manufacturer’s instructions. Brieﬂy, 10 ng of genomic DNA were used for
preparation of barcoded PCR-libraries using the comprehensive cancer
panel. Libraries (100 pM of each primer pool per cell line) were mixed,
ampliﬁed and bead-coupled by emulsion PCR using the OneTouch
2 system. Sequencing of duplexed samples was performed on the Ion
Personal Genome Machine (PGM) System and a 318v2 chip (all equipment
from Thermo Fisher Scientiﬁc, Waltham, MA, USA). Variant call ﬁles were
analyzed by our in-house pipeline and mutations were selected regarding
prediction of potential impact on protein function by algorithms SIFT/
PolyPhen54,55 and MutationTaster.56 Analysis of CNV was performed with R
package CNVPanelizer using BAM/BAI sequencing output ﬁles. Determina-
tion of CNVs of resistant MeWo cells was referenced to sensitive
(MeWoPar) cells.
Statistics
All quantitative real-time reverse transcriptase–PCR data are presented as
mean± s.d. values. Where indicated, Student’s t-test (two-tailed) was used
to compare two groups. A P-value ⩽ 0.05 is considered statistically
signiﬁcant. Center values shown represent median values. Data sets
subjected to pairwise comparisons performed using Student’s t-test were
checked for normality and variance among groups via calculating
Pearson’s coefﬁcients fell within a range of ± 0.8. For statistics of microarray
data, see section Gene expression proﬁling.
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